The Renin-Angiotensin System in Parkinson's Disease

· · ·
· International Review of Movement Disorders Book 9 · Academic Press
Ebook
422
Pages
Eligible
This book will become available on October 1, 2025. You will not be charged until it is released.

About this ebook

The book is organized into sections/chapters. Section I, The Renin-Angiotensin-Aldosterone System (RAAS) in health and disease, conveys topics like an overview and history of RAAS discovery and its significance in cardiovascular physiology, the RAAS in the cardiovascular system, including the cardiorenal axis, and other RAAS endocrine systems (in the liver, lungs, adrenal glands, and testes). RAAS pathways and second messengers (Cyclic AMP, Calcium), and receptors [AT1R, AT2R, MasR binding to the vasodilator angiotensin-(1-7)], medications targeting the RAAS, and effects of the RAAS on inflammation. Oxidative stress, vascular smooth muscle contraction, endothelial dysfunction, fibrosis, and the hypertrophic, anti-apoptotic, and pro-mitogenic effects of Angiotensin II. RAAS local brain systems and pleiotropic effects, including neuroinflammation, autophagy, endoplasmic reticulum stress, and mitochondrial dysfunction. Section II, the Renin-Angiotensin System (RAS) in Parkinson's disease, deals with general considerations, pathogeny and pharmacotherapeutics, the RAS and Alzheimer's disease and other neurodegenerative diseases, neuroprotective and anti-inflammatory properties of AT2 in motor neuron disease treatment, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA); RAS modulation of dopaminergic neurotransmission: effects on Parkinson's disease motor symptoms, motor fluctuations, memory, cognition and mood; ACEIs and ARBs' therapeutic benefits on mood and depressive symptoms; brain RAS as a potential therapeutic target in psychiatric disorders; the risk of Parkinson's disease and the use of Renin-angiotensin modulators; brain RAS regulation of stress and neuroinflammation, and participation of the hypothalamic-pituitary-adrenal axis; risk of Parkinson's disease and the use of RAS modulators; the relationship between RAS, COVID-19, and Parkinson's disease; RAS, Parkinson, and COVID-19: ACE2 and post COVID-19 parkinsonism; the relationship between RAS and other pathological conditions that increase PD risk. RAS role in the pathophysiology of diabetes and complications — nephropathy and retinopathy; gut microbiota and local gastrointestinal RAS two-way interaction; gut dysbiosis and impaired renin-angiotensin system (RAS) function in cognitive decline and neurodegeneration; gut microbiota impact on RAS-related disorders; gastrointestinal dopaminergic and renin-angiotensin systems; gut ACE2, probiotics supplementation, and diabetic retinopathy in type 1 diabetes; Ang-(1-7) protection in diabetes and diabetic retinopathy; ACE2 gene therapy improvement of glycemic control in diabetic mice. - The Renin-Angiotensin-Aldosterone System (RAS) in health and disease. - RAS pathways and second messengers (Cyclic AMP, Calcium), and receptors [AT1R, AT2R, MasR binding to the vasodilator angiotensin-(1-7)], medications targeting the RAS. - Brain RAS and other local RAS pathways. Neurodegenerative disorders. Gut microbiota and local gastrointestinal RAS two-way interaction; gut dysbiosis and impaired renin-angiotensin system (RAS) function in cognitive decline and neurodegeneration.

About the author

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

Cristian Falup-Pecurariu is Head of the Department of Neurology, County Clinic Hospital from Brasov, and is Full Professor of Neurology at the Transilvania University from Brasov, Romania. He received his medical degree from the University of Medicine and Pharmacy “Iuliu Hatieganu from Cluj-Napoca. He hold a 1 year fellowship of the European Neurological Society in movement disorders at Hospital Clinic, University of Barcelona, Spain. During his career Cristian Falup-Pecurariu was President of the European Association of Young Neurologists and Trainees (EAYNT), EAYNT Liasion Officer with World Federation of Neurological Society, co-representative of Europe on the International Working Group for Young Neurologists and Trainees (World Federation of Neurology). He was also Secretary of the EFNS/MDS-ES Panel on Movement Disorders, member of the Educational Committee of MDS-ES, member of the MDS Leadership Task Force and European Academy of Neurology Scientific Panel Movement Disorders, member of the Teaching Course sub-Committee of the European Academy of Neurology (EAN), currently being member of the Program Committee of EAN. Falup-Pecurariu is former Chair of the Education Committee of the MDS-ES, former member of the Executive Committee of MDS-ES, former member of the International Executive Committee of MDS. He is the initiator and Course Director of the Movement Disorders Teaching Course held in Brasov (12th editions). His research focuses on motor and non-motor aspects of Parkinson’s diseases.

Santiago Perez-Lloret MD PhD, is a leading expert in neurophysiology and neuropharmacology with more 130 papers published in international medical journals (Scopus H-index=35). After obtaining his MD and PhD in the University of Buenos Aires, Argentina, he pursued master courses in pharmacoepidemiology, clinical pharmacology and biostatistics at the Universities of Toulouse, Bordeaux and Paris, France. Dr. Perez-Lloret is an Assistant professor of Neurophysiology at the Medicine School of the University of Buenos Aires and a Senior Researcher at the Argentinean National Research Council. He is the director of the Health, Quality of Life, and Environment Unit at the Catholic University of Argentina and Editor-in-Chief of the Neurodegenerative Diseases International journal. He is a Fulbright scholar since 2002 and member of the Sigma Xi society. He is a member of the Evidence-Based Medicine Committee of the International Parkinson’s Disease and Movement Disorder Society (MDS).

Dr. Matilde Otero-Losada graduated at the School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) Argentina, pursued her studies in Neuropharmacology getting her Sci.D. in Neuropharmacology (UBA, Argentina) and completing her Ph.D. in Psychiatry at the Wolverhampton University, WLV, UK. Her following studies in Psychometrics and Statistical Methods, Radioisotopes and Radiochemistry, Signal Processing and Microcomputers, took her to the University of California San Diego (UCSD) for training in human Psychophysics. Back to Argentina, she carried on studying smell, taste and trigeminal perception at the Hospital de Clínicas, UBA. Focused on the study of metabolic syndrome, soft drinks and cardiovascular-renal morbidity for the last ten years, in the last two years she is back to her roots: Neurosciences. With over 90 papers published in prestigious journals indexed in PubMed, Embase and Scopus and book chapters authored, as Senior Researcher of the National Research Council (Argentina), she customarily reviews manuscripts and is acknowledged in scientific writing, and editorial capacities.

Reading information

Smartphones and tablets
Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.
Laptops and computers
You can listen to audiobooks purchased on Google Play using your computer's web browser.
eReaders and other devices
To read on e-ink devices like Kobo eReaders, you'll need to download a file and transfer it to your device. Follow the detailed Help Center instructions to transfer the files to supported eReaders.